68 Magnetic Tracer Increases Surgical Productivity and Reduces Time to Surgery When Compared With Standard Lymph Node Mapping Modalities

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 62-63

Table. Magnetic Tracer Increases Surgical Productivity and Reduces Time to Surgery When Compared With Standard Lymph Node Mapping Modalities

Table. Magnetic Tracer Increases Surgical Productivity and Reduces Time to Surgery When Compared With Standard Lymph Node Mapping Modalities

Background

Delayed cancer surgery is a core challenge faced by large-volume hospitals. This is influenced by long workups, operating room (OR) access, scheduling across multiple service lines, and continuing institutional cost pressures. The Commission on Cancer recommends that breast surgery be performed within 60 days of diagnosis. Standard tracers contribute to delays due to scarcity of products and appointments and increase in efficiency and cost due to multiple patient visits. A nonradioactive magnetic tracer (Magtrace) can replace a standard tracer, resulting in reduced cost and increased OR utilization. The aim of this study was to investigate the impact of the magnetic tracer (MT) on hospital workflows in a high-volume nonacademic medical center.

Methods

A retrospective analysis of 3 surgeons (A, B, C) over 3 years (March to August of 2021, 2022, and 2023) performing breast surgery. Surgeon A adopted the MT in March 2023 while B and C continued with Tc99 and blue dye. Outcomes collected included the number of surgeries performed, the number of days between referral and surgery, and the supply costs of the tracers.

Results

A total of 1665 patient records were analyzed (Table). Post MT adoption, surgeon A saw an increase in monthly breast surgical volume by 8 additional surgeries (47.5 in 2023 vs 39.5 in 2021-22, P = .0882). Surgeons B and C observed a decrease in volumes (surgeon B, 25.3 patients vs 32.23, P = .0133; surgeon C, 18.2 vs 21.4, P = .2468). Surgeon A experienced a reduction in the average time from referral to surgery by 11 days (from 80 to 69 days). The cost analysis revealed that MT was $656.65 per patient whereas the average Tc99 cost was $854.66 and isosulfan blue (BD) was $979.73. Per-patient cost savings were $198.01 when compared with Tc99 alone and $1177.74 when compared with Tc99 and BD.

Conclusions

Although there are many factors contributing to OR access and surgeon volume, the use of MT in a high-volume, nonacademic United States center may increase surgical volumes and reduce the time from referral to surgery. This approach not only improves hospital efficiency but also offers potential cost savings and scheduling benefits. These finding suggest that the MT may contribute to broader efficiencies in cancer care and may facilitate COC compliance. Further data collection is underway to monitor trends over time with wider adoption of the MT platform across surgeons.

Articles in this issue

46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
46 Comparative Analysis of Breast Conserving Therapy vs Mastectomy in Multifocal and Multicentric Breast Cancer: A Review of the Literature
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
47 Can We Identify Factors That Predict DCIS Upgrade to Invasive Cancer at Mastectomy?
48 The Era ‘or Error’ of Second Localization Procedures
48 The Era ‘or Error’ of Second Localization Procedures
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
51 Ductal Carcinoma In Situ With Microinvasion on Biopsy—What Are the Predictors of Upstaging?
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
54 The Evaluation of Expression Levels of CXCR4, CXCL12, and LASP1 Genes in Peripheral Blood Samples of Breast Cancer Patients
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left  Breast Cancer
55 Language as a Barrier to Deep Inspiration Breath Hold (DIBH) Radiation Therapy for Left Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
57 Addressing Barriers to Identifying Patients With HER2-Low Metastatic Breast Cancer in a Large Community Oncology Practice
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
58 Prospective Longitudinal Assessment of Financial Toxicity Among Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
59 Acceptability of Microbiome Sampling-Based Surgical Oncology Research in Minority Breast Cancer Patients
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast  Cancer in the United States by Palliative Care Utilization
60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
61 High-Risk Screening Compliance in Women Diagnosed With Breast Cancer and a History of Thoracic Radiation Prior to Age 30
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table